Chardan Capital Comments on MeiraGTx FY2026 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX) – Analysts at Chardan Capital issued their FY2026 earnings estimates for MeiraGTx in a research report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($1.09) for the year. Chardan Capital currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share.

Separately, Royal Bank of Canada lifted their target price on shares of MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Monday, March 17th.

MeiraGTx Stock Down 0.8 %

Shares of NASDAQ:MGTX opened at $7.33 on Thursday. The company has a market capitalization of $578.01 million, a price-to-earnings ratio of -6.06, a PEG ratio of 0.37 and a beta of 1.23. MeiraGTx has a 12-month low of $3.85 and a 12-month high of $8.75. The business has a 50-day moving average price of $6.83 and a 200 day moving average price of $6.06. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The firm had revenue of $21.39 million during the quarter, compared to analysts’ expectations of $1.50 million.

Hedge Funds Weigh In On MeiraGTx

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. grew its position in MeiraGTx by 106.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company’s stock worth $30,000 after purchasing an additional 2,515 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in MeiraGTx by 68.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company’s stock valued at $30,000 after acquiring an additional 2,016 shares during the last quarter. BNP Paribas Financial Markets raised its stake in MeiraGTx by 142.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock valued at $39,000 after acquiring an additional 5,476 shares during the last quarter. Polymer Capital Management US LLC purchased a new position in shares of MeiraGTx in the 4th quarter valued at approximately $88,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of MeiraGTx by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,571 shares of the company’s stock worth $101,000 after purchasing an additional 1,685 shares during the period. Institutional investors and hedge funds own 67.48% of the company’s stock.

Insider Transactions at MeiraGTx

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Richard Giroux sold 24,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the completion of the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. This trade represents a 2.75 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.